… inflammation. This review gives an overview of the role of inflammation in the pathogenesis
of COVID-19, critically examines the pharmacologic agents that target inflammation and the …

… coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019
(COVID-19… underlying the clinical manifestations of COVID-19 is vital for the identification …

… COVID-19 presents a wide spectrum of clinical manifestations, which ranges … COVID-19
and its etiological agent SARS-CoV-2, stressing the similarities with other severe coronavirus …

… systemic inflammatory response in COVID-19 might be crucial… monoclonal-antibody
tocilizumab on COVID-19 survival. It is … In conclusion, when treating COVID-19, physicians should …

… recovers from COVID-19 and an associated reduction in inflammation. Finally, at week 3
post-admission, NLR loses its clinical utility to prognosticate severe COVID-19 outcomes. …

… COVID-19 disease. Infection followed by cytokine storm leads to more severe inflammation
… aimed to introduce important biomarkers related to coagulation in patients with COVID-19. …

… Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage
to the respiratory tract, including the lung: coronavirus disease (COVI-19)… When COVI-19 …

… disease 2019 (COVID-19) is … in COVID-19 is the result of the interplay between inflammation
and endotheliopathy. Elevated interleukin-6 (IL-6) characterizes COVID-19 inflammation …

… Compared to HS, we found that COVID-19 survivors still exhibited systemic inflammation,
as evidenced by significant changes in the levels of multiple inflammatory proteins in plasma …

… Lastly, we tried to understand if pulmonary inflammation correlates with peripheral one, but
… We believe that a significant role in driving lung inflammation in COVID-19 patients has to be …